Being tested
Brain or nerve stimulation: improve symptoms or function in MS (type not specified)
MS (type not specified) · Brain or nerve stimulation
Trials are running now and no controlled trial has a readable result yet.
- Trials
- 89
- Running now
- 31
- Controlled phase 2/3 trials
- 0
- People in controlled trials
- 0
How the verdict was reached
Phase 3 results not all read yet
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| Neuromodulation device, trial | Not a drug-phase study | Not reported | 2006 | No results found | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 80 | 2006 | No results found | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 16 | 2006 | Met its main goal | Not counted: not randomised |
| TES | Not a drug-phase study | 97 | 2013 | No results found | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 32 | 2014 | No results found | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 29 | 2014 | No results found | Not counted: not randomised |
| PDMSLac | Not a drug-phase study | 34 | 2014 | No results found | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 6 | 2014 | No results found | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 7 | 2014 | No results found | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 180 | 2016 | Still running | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 58 | 2016 | Stopped | Not counted: phase 1 or phase 4 |
| Exercise rehabilitation, trial | Not a drug-phase study | 31 | 2016 | No results found | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 14 | 2016 | No results found | Not counted: not randomised |
| Device other, trial | Not a drug-phase study | 30 | 2017 | No results found | Not counted: not randomised |
| Diagnostic, trial | Not a drug-phase study | 60 | 2017 | No results found | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 30 | 2017 | No results found | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 5 | 2017 | Stopped | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 40 | 2014 | No results found | Not counted: not randomised |
| Exercise rehabilitation, trial | Not a drug-phase study | 136 | 2018 | Paper found, not read | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 0 | 2020 | Stopped | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 90 | 2019 | Paper found, not read | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 0 | 2020 | Stopped | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 12 | 2019 | No results found | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 122 | 2019 | Paper found, not readReported: mixed | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 13 | 2018 | No results found | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 6 | 2019 | No results found | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 10 | 2019 | No results found | Not counted: phase 1 or phase 4 |
| Exercise rehabilitation, trial | Not a drug-phase study | 40 | 2020 | No results found | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 40 | 2020 | No results found | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 60 | 2020 | No results found | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 30 | 2020 | No results found | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 23 | 2020 | Paper found, not read | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 20 | 2020 | No results found | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 7 | 2021 | No results found | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 36 | 2020 | No results found | Not counted: not randomised |
| NEUROECO | Not a drug-phase study | 30 | 2021 | No results found | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 100 | 2021 | Still running | Not counted: not randomised |
| CONTINENCE | Not a drug-phase study | 126 | 2022 | Paper found, not read | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 16 | 2021 | Paper found, not read | Not counted: not randomised |
| Exercise rehabilitation, trial | Not a drug-phase study | 80 | 2023 | Paper found, not read | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 34 | 2022 | No results found | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 60 | 2023 | Still running | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 36 | 2022 | No results found | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 20 | 2021 | Paper found, not read | Not counted: not randomised |
| FETEM | Phase 3 | 144 | 2022 | Paper found, not read | Counts only if it beats amantadine |
| Neuromodulation device, trial | Not a drug-phase study | 36 | 2023 | No results found | Not counted: phase 1 or phase 4 |
| Exercise rehabilitation, trial | Not a drug-phase study | 30 | 2023 | No results found | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 36 | 2023 | No results found | Not counted: phase 1 or phase 4 |
| MSBLADDER | Not a drug-phase study | 29 | 2023 | Still running | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 22 | 2023 | No results found | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 42 | 2023 | No results found | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 64 | 2024 | No results found | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 72 | 2024 | Still running | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 12 | 2024 | No results found | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 53 | 2023 | Paper found, not read | Not counted: phase 1 or phase 4 |
| MSBAL | Not a drug-phase study | 46 | 2024 | Still running | Not counted: not randomised |
| Digital health, trial | Not a drug-phase study | 45 | 2024 | No results found | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 60 | 2024 | No results found | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 30 | 2025 | No results found | Not counted: not randomised |
| EXOSEP | Not a drug-phase study | 34 | 2022 | Paper found, not read | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 34 | 2023 | No results found | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 40 | 2025 | Still running | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 76 | 2025 | Still running | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 24 | 2025 | Still running | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 65 | 2024 | Still running | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 85 | 2024 | Still running | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 78 | 2025 | Still running | Not counted: phase 1 or phase 4 |
| CRESTMS | Not a drug-phase study | 40 | 2023 | No results found | Not counted: phase 1 or phase 4 |
| TACS-CI-IIDDs | Not a drug-phase study | 128 | 2025 | Still running | Not counted: phase 1 or phase 4 |
| tDCScog | Not a drug-phase study | 80 | 2024 | Still running | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 30 | 2025 | Still running | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 15 | 2025 | Still running | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 60 | 2025 | Still running | Not counted: phase 1 or phase 4 |
| CeV | Not a drug-phase study | 70 | 2025 | Still running | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 24 | 2025 | Still running | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 30 | 2026 | Still running | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 24 | 2026 | Still running | Not counted: phase 1 or phase 4 |
| Device other, trial | Not a drug-phase study | 90 | 2026 | Still running | Not counted: not randomised |
| PENS-TENS-MS | Not a drug-phase study | 28 | 2026 | Paper found, not read | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 12 | 2026 | Still running | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 14 | 2026 | No results found | Not counted: not randomised |
| CerebellertDCS | Not a drug-phase study | 40 | 2026 | Still running | Not counted: phase 1 or phase 4 |
| Exercise rehabilitation, trial | Not a drug-phase study | 60 | 2025 | Still running | Not counted: phase 1 or phase 4 |
| AROMA-MS | Not a drug-phase study | 60 | 2026 | Still running | Not counted: phase 1 or phase 4 |
| FES in MS | Not a drug-phase study | 70 | 2026 | Still running | Not counted: phase 1 or phase 4 |
| Neuromodulation device, trial | Not a drug-phase study | 75 | 2021 | Still running | Not counted: not randomised |
| Neuromodulation device, trial | Not a drug-phase study | 60 | 2018 | Still running | Not counted: not randomised |
| TMS-SPASMS | Not a drug-phase study | 40 | 2026 | Still running | Not counted: phase 1 or phase 4 |
| EXO-MS | Not a drug-phase study | 100 | 2026 | Still running | Not counted: phase 1 or phase 4 |
Counted: 0. Will count later: 1. Not counted: 88.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Nov 2026Trials: 90 → 89
- Oct 2026Trials: 99 → 90
- Oct 2026First listed as Being tested
Related hypotheses
- Brain or nerve stimulation: improve symptoms or function in NMOSD
- Brain or nerve stimulation: improve symptoms or function in optic neuritis
- Brain or nerve stimulation: improve symptoms or function in primary progressive MS
- Brain or nerve stimulation: improve symptoms or function in relapsing MS
- Brain or nerve stimulation: improve symptoms or function in relapsing and progressive MS
- Brain or nerve stimulation: improve symptoms or function in secondary progressive MS
Assembled by software from public sources.